Genetic variants and early cigarette smoking and nicotine dependence phenotypes in adolescents
Article [Version of Record]
Abstract(s)
Background: While the heritability of cigarette smoking and nicotine dependence
(ND) is well-documented, the contribution of specific genetic variants to specific
phenotypes has not been closely examined. The objectives of this study were to
test the associations between 321 tagging single-nucleotide polymorphisms
(SNPs) that capture common genetic variation in 24 genes, and early smoking and
ND phenotypes in novice adolescent smokers, and to assess if genetic predictors
differ across these phenotypes.
Methods: In a prospective study of 1294 adolescents aged 12–13 years recruited
from ten Montreal-area secondary schools, 544 participants who had smoked at
least once during the 7–8 year follow-up provided DNA. 321 single-nucleotide
polymorphisms (SNPs) in 24 candidate genes were tested for an association with
number of cigarettes smoked in the past 3 months, and with five ND phenotypes (a
modified version of the Fagerstrom Tolerance Questionnaire, the ICD-10 and three
clusters of ND symptoms representing withdrawal symptoms, use of nicotine for
self-medication, and a general ND/craving symptom indicator).
Results: The pattern of SNP-gene associations differed across phenotypes.
Sixteen SNPs in seven genes (ANKK1, CHRNA7, DDC, DRD2, COMT, OPRM1,
SLC6A3 (also known as DAT1)) were associated with at least one phenotype with a
p-value ,0.01 using linear mixed models. After permutation and FDR adjustment, none of the associations remained statistically significant, although the p-values for
the association between rs557748 in OPRM1 and the ND/craving and selfmedication phenotypes were both 0.076.
Conclusions: Because the genetic predictors differ, specific cigarette smoking and
ND phenotypes should be distinguished in genetic studies in adolescents. Fifteen
of the 16 top-ranked SNPs identified in this study were from loci involved in
dopaminergic pathways (ANKK1/DRD2, DDC, COMT, OPRM1, and SLC6A3).
Impact: Dopaminergic pathways may be salient during early smoking and the
development of ND.